Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.

NCT06634927 | Completed Phase 1

• 1 other identifier: HDG1901-103
• Study Type: interventional
• Target: 68
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a randomized, open-label, single-dose, parallel-controlled biosimilar comparison study comparing the pharmacokinetics, safety and immunogenicity of the investigational drug and the active comparator in healthy adult subjects. Eligible healthy participants will be screened and randomly assigned to the experimental group and the active comparator group at a ratio of 1:1 , semaglutide injection or Ozempic® injection 0.25mg abdominal subcutaneous injection will be given according to their groups. Follow-up for 5 weeks after administrtion. Studies included a screening period (up to 2 weeks), baseline, administration (single dose), and a follow-up period (5 weeks). The duration of the study will be approximately 7 weeks for a participant.

Conditions

Type 2 Diabetes

Keywords

Glucagon-Like Peptide-1 Receptor Agonists; semaglutide

Outcome Measures

Primary Outcomes (3)

• AUC0-inf

  Area Under the Concentration-time curve from time zero to infinite time

  -60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration

• AUC0-t

  Area Under the Concentration-time curve from time zero to the last measurable concentration

  -60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration

• Cmax

  Maximum concentration of the active substance in the blood plasma of participants during the observation period

  -60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration

Secondary Outcomes (6)

• AUC_%Extrap

  -60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration

• Tmax

  -60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration

• t 1/2

  -60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration

• λz

  -60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration

• CL

  -60minutes and 6, 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 144, 336, 504, 672, 840 hours after administration

Study Arms (2)

Experimental group

EXPERIMENTAL

Experimental group: Semaglutide injection, specifications: 1.34 mg/mL, 1.5 mL (pre-filled injection pen), 0.25 mg , subcutaneous abdominal injection.

Drug: HDG1901

Active Comparator

ACTIVE COMPARATOR

Control group: Ozempic ® injection, 1.34 mg/mL, 1.5 mL (pre-filled injection pen), 0.25 mg , subcutaneous injection into the abdomen.

Drug: Ozempic®

Interventions

Ozempic® DRUG

Participants will be given Ozempic ® injection 0.25mg abdominal subcutaneous injection.

Active Comparator

HDG1901 DRUG

Participants will be given HDG1901 injection 0.25mg abdominal subcutaneous injection.

Experimental group

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Participants must meet all of the following criteria to be enrolled in the study:
• Voluntarily participate in the trial and sign the informed consent; Willing and able, in the investigator\'s judgment, to comply with all experimental requirements and restrictions;
• Healthy men and women, aged 18 to 55 years old (including);
• Body mass index (BMI) 19.0\~25.0 kg/m2 (including), weight ≥50.0 kg;
• Physical examination, vital signs, 12-lead electrocardiogram (ECG), clinical laboratory examination, no clinically significant abnormalities;

You may not qualify if:

• Subjects who meet any of the following criteria will be excluded:
• Have a history of clinically serious disease or currently have any clinically significant cardiovascular, metabolic, endocrine, kidney, liver, gastrointestinal, hematological, respiratory, cutaneous, neurological, gynecological, psychiatric or other disease;
• A history of medullary thyroid carcinoma (MTC), multiple endocrine adenoma (MEN) 2A or 2B syndrome, or related family history; Or other malignant tumor history;
• Subjects with a history of acute and chronic pancreatitis, symptomatic gallbladder history, pancreatic injury history and other high-risk factors that may lead to pancreatitis;
• In the screening period, calcitonin was greater than the upper limit of normal;
• Patients with HbA1c greater than 6.5% during the screening period;
• Those who smoked more than 5 cigarettes per day in the 3 months before screening and those who could not smoke during the whole test period;
• Those who have a history of alcohol abuse in the six months prior to screening, or who cannot abstain from alcohol during the test period;
• Consume any food or drink containing caffeine, alcohol, xanthine or grapefruit (such as coffee, strong tea, chocolate, etc.) within 48 hours before check-in;
• Known or suspected allergy to semaglutide injection or similar products and excipients;
• Participants in clinical trials of any approved or unapproved investigational drug/device within 90 days prior to screening;
• Pregnant and lactating female subjects;
• Patients with difficulty in venous blood collection;
• Those who were vaccinated within 4 weeks prior to screening or planned to be vaccinated during the trial;
• People who donate blood or lose more than 400 mL of blood or receive blood transfusions or use blood products in the 3 months prior to screening;

Sponsors & Collaborators

• Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.: lead

Study Sites (1)

The Second Hospital of Anhui Medical University

Hefei, Anhui, 230601, China

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

semaglutide

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 24, 2024
• First Posted: October 10, 2024
• Study Start: September 22, 2024
• Primary Completion: November 14, 2024
• Study Completion: February 12, 2025
• Last Updated: August 1, 2025

Record last verified: 2024-09

Locations

CN (1)